Hims & Hers to announce Q2 2026 results on August 10

0 min read Updated on 14 Jul 2026, 02:54 AM

Reviewed by

Shriram SScanX News Team

AI Summary

Hims & Hers Health, Inc. will release its Q2 2026 financial results on August 10, 2026, followed by a conference call. Access details for the call and webcast are provided.

*this image is generated using AI for illustrative purposes only.

Hims & Hers Health, Inc. will announce its second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET on the same day.

Conference Call Details

Investors can access the conference call by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants. The conference ID for the call is 1704296.

A live audio webcast of the call will be available at https://investors.hims.com . The webcast will be archived for one year following the event.

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. operates as a health and wellness platform. The company focuses on providing personalized care designed for results to help individuals achieve better health.

What key metrics will investors be focusing on during the Q2 2026 earnings call?

How might Hims & Hers' performance in Q2 2026 impact its stock price and market position?

What strategic initiatives or product launches could Hims & Hers announce during the call?

Read Next Article

B of A Securities maintains Neutral on Hims & Hers Health, raises target to $37

0 min read Updated on 09 Jul 2026, 05:51 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

AI Summary

B of A Securities analyst Allen Lutz maintained a Neutral rating on Hims & Hers Health, raising the price target to $37 from $36. The revision suggests a balanced risk-reward profile for the NYSE-listed telehealth company.

*this image is generated using AI for illustrative purposes only.

B of A Securities analyst Allen Lutz has maintained a Neutral rating on Hims & Hers Health while raising the price target to $37 from the previous $36. The revised target indicates a modest adjustment in the valuation outlook for the company, which is listed on the NYSE under the ticker HIMS.

The decision to hold the rating at Neutral suggests that the firm sees the stock's risk-reward profile as balanced at the new price level. While the increased target acknowledges potential upside, the stance implies that the stock may not offer a significant edge compared to other opportunities in the sector at this time.

Rating and Price Target Details

The following table outlines the revised ratings and price targets set by B of A Securities:

Metric	Value
Rating	Neutral
Previous Price Target	$36
New Price Target	$37
Exchange	NYSE
Ticker Symbol	HIMS

Hims & Hers Health operates as a telehealth platform, providing access to various health and wellness products. The company's performance is closely watched by investors tracking the digital health sector.

What specific factors could drive Hims & Hers Health to outperform the Neutral rating?

How might upcoming regulatory changes impact the telehealth sector's growth trajectory?

What competitive advantages does Hims & Hers have over other digital health platforms?